Vilsbøll T, et al. - In patients grouped by sex, age (<65 years, ≥65 years) and diabetes duration (<10 years, ≥10 years), researchers examined the impacts of insulin degludec/liraglutide fixed-ratio combination (IDegLira) vs comparators on cardiovascular (CV) risk markers from DUAL II (vs insulin degludec), DUAL V (vs insulin glargine 100 units/mL) and DUAL VII (vs basal–bolus therapy) in this post hoc analysis. According to results, heart rates were higher with IDegLira vs comparators in all three trials; significantly higher diastolic BP was seen in males (DUAL V). Differences in between sexes were seen in waist circumference (DUAL II), systolic BP (DUAL II, DUAL V) and triglycerides (DUAL VII), and between diabetes durations in LDL-C (DUAL V). After 26 weeks of treatment, IDegLira vs basal insulin or basal–bolus therapy was linked to a general improvement in CV risk markers.